COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Tsirigotis, P. [2 ]
Chondropoulos, S. [2 ]
Konstantellos, I [2 ]
Qeodurasoy, N. [3 ]
Spousta, T. [4 ]
Van Hees, F. [4 ]
Smith, N. [4 ]
Doble, B. [5 ]
机构：
[1] Econcare LP, Athens, Greece
[2] Attikon Univ, Gen Hosp, Athens, Greece
[3] Gilead Sci Hellas, Palaio Faliro, Greece
[4] Maple Hlth Grp LLC, New York, NY USA
[5] Kite A Gilead Co, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE265
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/ REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN THE UNITED KINGDOM
    Spousta, T.
    Feng, C.
    van Hees, F.
    Wade, S.
    Doble, B.
    VALUE IN HEALTH, 2023, 26 (12) : S156 - S156
  • [2] Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Kopmar, Noam E.
    Cassaday, Ryan D.
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1587 - 1596
  • [3] BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA: COST-EFFECTIVENESS IN THE CLINICAL SUBSETS
    Marchetti, Monia
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 198 - 198
  • [4] Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
    Muhsen, Ibrahim
    Advani, Anjali S.
    Roloff, Gregory W.
    Jeyakumar, Nikeshan
    Miller, Katharine
    Zhang, Amy
    Sutherland, Katherine C.
    Grunwald, Michael R.
    Kota, Vamsi K.
    Boccucci, Jacob
    Ulrickson, Matthew
    Sasine, Joshua
    Aldoss, Ibrahim
    Othman, Tamer
    Vasu, Sumithira
    Reshef, Ran
    Luskin, Marlise R.
    Chen, Evan C.
    Lin, Chenyu
    Langston, Amelia
    Cassaday, Ryan D.
    Kopmar, Noam E.
    Tsai, Stephanie B.
    O'Connor, Timothy E.
    Hilal, Talal
    Faramand, Rawan
    Park, Jae H.
    Valtis, Yannis K.
    Solh, Melhem M.
    Bezerra, Evandro
    Leonard, Jessica T.
    Dekker, Simone E.
    Majhail, Navneet
    Battiwalla, Minoo
    Malik, Shahbaz A.
    Mathews, John
    Shaughnessy, Paul
    Mountjoy, Luke
    Hoeg, Rasmus T.
    Oliai, Caspian H.
    Gupta, Vishal
    Koura, Divya
    Dykes, Kaitlyn C.
    Logan, Aaron C.
    Kumaran, Muthu, V
    Stock, Wendy
    Schwartz, Marc
    Bachanova, Veronika
    Tracy, Sean
    O'Dwyer, Kristen M.
    BLOOD, 2024, 144 : 523 - 526
  • [5] Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma
    Marchetti, M.
    Visco, C.
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1442 - 1450
  • [6] FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Bouchkouj, Najat
    Lin, Xue
    Wang, Xiaofei
    Przepiorka, Donna
    Xu, Zhenzhen
    Purohit-Sheth, Tejashri
    Theoret, Marc
    ONCOLOGIST, 2022, 27 (10): : 892 - 899
  • [7] The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    O'Connor, Timothy E.
    Lin, Chenyu
    Roloff, Gregory W.
    Zhang, Amy
    Aldoss, Ibrahim
    Faramand, Rawan
    Kopmar, Noam E.
    Dykes, Kaitlyn C.
    Jeyakumar, Nikeshan
    Dekker, Simone E.
    Gupta, Vishal K.
    Ahmed, Mohamed
    Logan, Aaron C.
    Zambrano, Hector
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Mathews, John
    Shaughnessy, Paul
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    Sasine, Joshua
    Solh, Melhem M.
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Oliai, Caspian H.
    Bachanova, Veronika
    Stock, Wendy
    Cassaday, Ryan D.
    Shah, Bijal D.
    Miller, Katharine
    Muffly, Lori S.
    Galal, Ahmed
    BLOOD, 2023, 142
  • [8] Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
    Ionescu, Filip
    Faramand, Rawan
    Bailey, Hanna
    Bachmeier, Christina A.
    DiMaggio, Elizabeth
    Mohammed, Turab
    Isenalumhe, Leidy Lismeris
    Locke, Frederick L.
    Jain, Michael D.
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [9] Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
    Wang, Ying
    Lv, Lulu
    Song, Yongping
    Wei, Xudong
    Zhou, Hongsheng
    Liu, Qifa
    Xu, Kailin
    Yan, Dongmei
    Zhang, Cheng
    Liu, Shuangyou
    Jin, Jie
    Mei, Heng
    Niu, Ting
    Liang, Aibin
    Gu, Runxia
    Ren, Jienan
    Feng, Yi
    Jin, Wei
    Zhou, Yan
    Deng, Yiping
    Wang, Jianxiang
    BLOOD ADVANCES, 2025, 9 (04) : 836 - 843
  • [10] COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL, CAR-T) FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN GREECE
    Loupas, M. A.
    Theodoratou, D.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S112 - S112
12345